user warning: Got error -1 from storage engine query: taxonomy_node_get_terms /* Anonymous : taxonomy_node_get_terms */ SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 4683 ORDER BY v.weight, t.weight, t.name in /home/content/91/2523091/html/modules/taxonomy/taxonomy.module on line 632.

Time to go All-In on Celsion?

Submitted by Stockmaster2 on Mon, 01/07/2013 - 06:37

Shares of Celsion could double by the end of the month - or go to zero. Its fate will be decided by Phase III results.

Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.

This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.

Mastery Bottom Line

Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.